Novasep Successfully Priced Senior Secured Notes

Novasep Holding S.A.S. ("Novasep" or the "Company"), headquartered in Nancy, France, today announced that it successfully priced a Euro tranche of €270,000,000 aggregate principal of 9.625% Senior Secured Notes due 2016 and a U.S. dollar tranche of $150,000,000 aggregate principal of 9.750% Senior Secured Notes due 2016 (the "Senior Secured Notes").

The Company intends to use the net proceeds from the Senior Secured Notes Offering mainly to prepay all amounts outstanding under the Company's and its operating subsidiaries' existing senior facilities and mezzanine facilities.

About Novasep Holding S.A.S.

Novasep develops markets and operates innovative technologies providing life science industries with safe and cost-effective production of active molecules. The global manufacturing solutions offered by Novasep include process development services; purification equipment and systems; contract manufacturing services; and complex active molecules.

Customers include pharmaceutical companies such as Pfizer, Sanofi Aventis, Roche, Wyeth, Eli Lilly, Bristol Myers Squibb, GSK Biologicals, Gilead, UCB Pharma.

The company has six FDA inspected manufacturing plants in France, Germany and the Bahamas, two biopharmaceutical production sites in Belgium, R&D and equipment manufacturing facilities in the USA, China and France, and an office in Japan. It employs approximately 1,300 people and had annual revenues of EUR321 million in 2008. More than 2,000 systems designed and produced by Novasep are currently purifying active molecules throughout the world. The company holds more than 200 different patents covering its technologies and processes.

www.novasep.com

The press release shall not constitute an offer to sell or the solicitation of an offer to buy securities. There will not be any sale of these securities in any such state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or country.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act") and may not be offered and sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.
Neither this press release nor the offer of securities referred to therein constitute an "offre au public" within the meaning of Article L. 411-1 of the French Code monétaire et financier and Title I of Book II of the Règlement Général of the Autorité des marchés financiers. Consequently, the securities referred to herein may not be, directly or indirectly, offered or sold to the public in France and offers and sales of these securities will only be made in France to providers of the investment service of portfolio management for the account of third parties (personnes fournissant le service d'investissement de gestion de portefeuille pour le compte de tiers) and/or to qualified investors (investisseurs qualifiés) acting for their own accounts and/or to a closed circle of investors (cercle restraint d'investissuers) acting for their own accounts, as defined in, and in accordance with, Articles L. 411-2 and D. 411-1 to D. 411-4, D. 734-1, D-744-1, D. 754-1, D. 764-1 of the French Code monétaire et financier.

This press release may include projections and other "forward-looking" statements within the meaning of applicable securities laws. Any such projections or statements reflect the current views of Novasep about further events and financial performance. No assurances can be given that such events or performance will occur as projected and actual results may differ materially from these projections.
Within the United Kingdom, this announcement is directed only at persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("relevant persons"). The investment or investment activity to which this announcement relates is only available to and will only be engaged in with relevant persons and person who receive this announcement who are not relevant persons should not rely or act upon it.